RECRUITING

Deep Functional Phenotyping of the ALA Lung Health Cohort

Talk to us

Conditions

Lung Diseases

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: * air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).

Official Title

The American Lung Association (ALA) Deep Phenotyping Ancillary Study of the Lung Health Cohort (LHC)

Quick Facts

Study Start:2024-02-12
Study Completion:2026-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06177717

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 25-35 years at the time of the baseline examination
  2. * Able to read and understand English or Spanish
  3. * Has a social security number
  4. * Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.
  5. * Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant
  1. 1. Severe asthma, which is defined as any of the following:
  2. * Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid \[ICS\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
  3. * 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
  4. * One asthma hospitalization in the past 12 months
  5. 2. History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
  6. 3. Current pregnancy
  7. 4. History of cancer other than non-melanoma skin cancer
  8. 5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
  9. 6. Inability to comply with study procedures, including
  10. * Inability or unwillingness to provide informed consent
  11. * Inability to perform study measurements
  12. * Inability to be contacted by phone (via calls and/or text messaging) or email
  13. 7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
  14. 8. Institutionalization

Contacts and Locations

Study Contact

Meredith McCormack, MD
CONTACT
410-955-3467
mmccor16@jhmi.edu
Alexis Rea, MPH
CONTACT
443-287-8496
area5@jhu.edu

Principal Investigator

Meredith McCormack, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

University of Alabama
Birmingham, Alabama, 35294
United States
University of California, Los Angeles
Los Angeles, California, 90095
United States
National Jewish Health
Denver, Colorado, 80206
United States
Nemours Children's Jacksonville
Jacksonville, Florida, 32207
United States
Northwestern University
Chicago, Illinois, 60611
United States
University of Kansas
Kansas City, Kansas, 66103
United States
Johns Hopkins University
Baltimore, Maryland, 21218
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Duke University
Durham, North Carolina, 27710
United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27104
United States
University of Pittsburgh - Emphysema/COPD Research Center
Pittsburgh, Pennsylvania, 15213
United States
University of Vermont
Burlington, Vermont, 05446
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Meredith McCormack, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-12
Study Completion Date2026-07

Study Record Updates

Study Start Date2024-02-12
Study Completion Date2026-07

Terms related to this study

Additional Relevant MeSH Terms

  • Lung Diseases